A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Table 3 Baseline characteristics and responses of the MDS cohort (N = 8)

Patient	Age (years)	Disease subtype	Number of prior lines of therapy	Baseline bone marrow blasts	IPSS-R risk	Mutations	Best response	Duration of response (months)
#1	59	MDS	1	15%	Very high	TP53, BRINP3	Not evaluable	N/A
#2	71	MDS	2	4%	High	ASXL1, NF1, RUNX1, SF3B1, PHF6	Stable disease	5.1
#3	83	CMML	1	6%	Intermediate	SF3B1, SRSF2, ASXL1, RUNX1, SETBP1, PRPF40B	mCR	4.4
#4	74	MDS	1	3%	Very high	TP53	CR	14.8 (ongoing)
#5	49	CMML	2	11%	Very high	ASXL1, PTPN11, U2AF1	mCR	2.8
#6	72	MDS	1	2%	High	EZH2, SF3B1, TET2, RAD21	HI-P	10.9
#7	76	MDS	1	9%	High	TP53, ASXL2, ETV6, SETBP1, ZRSR2	mCR + HI-E + HI-N	8.0
#8	78	MDS	3	14%	Very high	IDH2, SRSF2, FLT3-D835, RUNX1	mCR + HI-N	3.9

Abbreviations: MDS, myelodysplastic syndrome; CMML, chronic myelomonocytic leukemia; IPSS-R, Revised International Prognostic Scoring System; CR, complete response; mCR, marrow complete response; HI, hematologic improvement; HI-E, HI with erythroid response; HI-N, HI with neutrophil response; HI-P, HI with platelet response

ISSN: 1756-8722